Persistence of influenza vaccine-induced antibody in lung transplant patients and healthy individuals beyond the season

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 12, 2012, Pages 1850-1853

  Severson, Jill J ^a   Richards, Katelyn R ^b   Moran, John J M ^a   Hayney, Mary S ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

Antibody; Immunosuppression; Influenza vaccine; Lung transplantation; Persistence; Waning

Indexed keywords

INFLUENZA VACCINE; VIRUS ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; FEMALE; GRAFT RECIPIENT; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; VIRUS STRAIN;

ANTIBODY; IMMUNOSUPPRESSION; INFLUENZA VACCINE; LUNG TRANSPLANTATION; PERSISTENCE; WANING;

ADULT; AGED; ANTIBODIES, VIRAL; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LONGITUDINAL STUDIES; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; SEROEPIDEMIOLOGIC STUDIES; TRANSPLANTATION;

EID: 84872224039     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.21735     Document Type: Article

References (19)

1. Billings JL, Hertz MI, Savik K, Wendt CH. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant 2002; 21:559-66; PMID:11983546; http://dx.doi.org/10.1016/S1053-2498(01)00405-3.
2. Billings JL, Hertz MI, Wendt CH. Community respiratory virus infections following lung transplantation. Transpl Infect Dis 2001; 3:138-48; PMID:11493396; http://dx.doi.org/10.1034/j.1399-3062.2001.003003138.x.
3. Vilchez R, McCurry K, Dauber J, Iacono A, Keenan R, Griffith B, et al. Influenza and parainfluenza respiratory viral infection requiring admission in adult lung transplant recipients. Transplantation 2002; 73:1075-8; PMID:11965034; http://dx.doi.org/10.1097/00007890-200204150-00010.
4. Khalifah AP, Hachem RR, Chakinala MM, Schechtman KB, Patterson GA, Schuster DP, et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med 2004; 170:181-7; PMID:15130908; http://dx.doi.org/10.1164/rccm.200310-1359OC.
5. Dopp JM, Wiegert NA, Moran JJM, Francois ML, Radford KL, Thomas H, et al. Effect of annual influenza immunization on antibody response in lung transplant patients. Prog Transplant 2009; 19:153-9; PMID:19588665.
6. Hayney MS, Welter DL, Francois M, Reynolds AM, Love RB. Influenza vaccine antibody responses in lung transplant recipients. Prog Transplant 2004; 14:346-51; PMID:15663020.
7. Mazzone PJ, Mossad SB, Mawhorter SD, Mehta AC, Schilz RJ, Maurer JR. The humoral immune response to influenza vaccination in lung transplant patients. Eur Respir J 2001; 18:971-6; PMID:11829104; http://dx.doi.org/10.1183/09031936. 01.00215201.
8. Guidance for Industry: Clinical data needed to support the licensure of seasonal inactivated influenza vaccines. Rockville, MD: Food and Drug Administration 2007.
9. Moran JJM, Rose WE, Darga AJ, Rohde KA, Hayney MS. Persistence of influenza vaccine-induced antibodies in lung transplant patients between seasons. Transpl Infect Dis 2011; 13:466-70; PMID:21615847; http://dx.doi.org/ 10.1111/j.1399-3062.2011.00654.x.
10. Song JY, Cheong HJ, Hwang IS, Choi WS, Jo YM, Park DW, et al. Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence. Vaccine 2010; 28:3929-35; PMID:20394719; http://dx.doi.org/10.1016/j.vaccine.2010.03.067.
11. Skowronski DM, Tweed SA, De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J Infect Dis 2008; 197:490-502; PMID:18275271; http://dx.doi.org/10.1086/524146.
12. Borrow R, Andrews N, Findlow H, Waight P, Southern J, Crowley-Luke A, et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 2010; 17:154-9; PMID:19906895; http://dx.doi.org/10.1128/CVI.00384-09.
13. Petrie JG, Ohmit SE, Johnson E, Cross RT, Monto AS. Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis 2011; 203:1309-15; PMID:21378375; http://dx.doi.org/10. 1093/infdis/jir015.
14. Powers DC, Belshe RB. Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. J Infect Dis 1993; 167:584-92; PMID:8440930; http://dx.doi.org/ 10.1093/infdis/167.3.584.
15. Powers DC, Hanscome PJ, Pietrobon PJ. In previously immunized elderly adults inactivated influenza A (H1N1) virus vaccines induce poor antibody responses that are not enhanced by liposome adjuvant. Vaccine 1995; 13:1330-5; PMID:8585289; http://dx.doi.org/10.1016/0264-410X(95)00002-I.
16. Associated Press. A vaccine has repetition need? This fall, perhaps not. Atlanta, GA; 2011.
17. Stephenson I, Das RG, Wood JM, Katz JM. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 2007; 25:4056-63; PMID:17412461; http://dx.doi.org/10.1016/j.vaccine.2007.02.039.
18. Gross PA, Russo C, Teplitzky M, Dran S, Cataruozolo P, Munk G. Time to peak serum antibody response to influenza vaccine in the elderly. Clin Diagn Lab Immunol 1996; 3:361-2; PMID:8705685.
19. Centers for Disease Control. Advanced Laboratory Techniques for Influenza Diagnosis. Atlanta, BA: Public Health Service; 1975.